to write publish a scientific paper 5th edition

anton calculus 6th edition

anton calculus 7th edition

Climate change means extreme heat will become the norm for millions across the world. We joined an experiment in the Saudi Arabian desert designed to find out what that means for our brains and bodies

Taylor Roades's images of a river in north-west Alaska that has turned orange because of global warming have won the New Scientist Editors Award at the Earth Photo competition

Italian canoes capable of transporting people and goods have been dated to the Neolithic period, suggesting there was a bustling trade across the Mediterranean Sea

Title: Gene 'Editing' in Dog Study Shows Promise for Kids With Muscular Dystrophy
Category: Health News
Created: 8/30/2018 12:00:00 AM
Last Editorial Review: 8/31/2018 12:00:00 AM

Title: AHA News: What Goes Into a Mediterranean Diet, and How to Get Started
Category: Health News
Created: 8/23/2022 12:00:00 AM
Last Editorial Review: 8/23/2022 12:00:00 AM

Title: Qigong Meditation for Beginners: Techniques, Benefits, and More
Category: Health and Living
Created: 8/24/2022 12:00:00 AM
Last Editorial Review: 8/24/2022 12:00:00 AM

Obidoxime chloride is an antidote for nerve gas intoxication. As an emergency medicine, it is being stored by the Israel Defense Forces (IDF) scattered throughout Israel in depots without a controlled environment (field conditions), thus being exposed to high and fluctuating temperatures. These conditions do not meet the manufacturer’s requirements. In addition, due to possible supply shortages, the utilization of expired batches was suggested. The current work investigated these matters. Long-term (15 years) storage under different conditions was initiated. Chemical stability and toxicity in rats were assessed. No difference was found between field conditions vs the controlled environment. The obidoxime assay remained >95% for 5 years and >90% for 7 years. The pH remained above the lower specification limit for 7–8 years. The major degradation product, 4-pyridinealdoxime, surpassed the allowed limit at 5 years. The content of total unknown impurities reached its maximum allowed by the IDF limit at 4–5 years. Threefold higher than clinically utilized doses of valid-to-date Toxogonin batches administered to rats did not cause any abnormality. However, expired batches produced significant toxic effects. Although no difference was found between storage of obidoxime ampoules when adhering to manufacturer’s recommendations vs field conditions, accumulation of degradants over the limit allowed by the IDF at 4–5 years of storage and the toxicity of the expired batches observed in rats led the IDF to a decision to shorten the shelf-life of this product from 5 to 4 years when stored in an uncontrolled environment of the Mediterranean climate.

Valve has announced Steam Deck OLED: Limited Edition White.

The handheld is a limited edition white version of the Steam Deck OLED that will be available in limited quantities for $679.

Pre-orders will open up on Steam on November 18 at 3:00 pm PT / 6:00 pm ET / 11:00 pm UK.

A life-long and avid gamer, William D'Angelo was first introduced to VGChartz in 2007. After years of supporting the site, he was brought on in 2010 as a junior analyst, working his way up to lead analyst in 2012 and taking over the hardware estimates in 2017. He has expanded his involvement in the gaming community by producing content on his own YouTube channel and Twitch channel. You can contact the author on Twitter @TrunksWD.

Full Article - https://www.vgchartz.com/article/463040/valve-announces-steam-deck-oled-limited-edition-white/

Sony Interactive Entertainment in a new video posted to YouTube revealed the PlayStation 5 Slim Digital Edition has been discounted by $70 and will be available for $379.99. The deal runs until December 24 "while supplies last."

No word yet if the standard PlayStation 5 or the recently released PlayStation 5 Pro will be discounted. The standard PS5 is priced at $499.99 and the PS5 Pro is priced at $699.99.

As of the time of writing, the discount isn't available yet at retailers or through PlayStation Direct.

A life-long and avid gamer, William D'Angelo was first introduced to VGChartz in 2007. After years of supporting the site, he was brought on in 2010 as a junior analyst, working his way up to lead analyst in 2012 and taking over the hardware estimates in 2017. He has expanded his involvement in the gaming community by producing content on his own YouTube channel and Twitch channel. You can contact the author on Twitter @TrunksWD.

Full Article - https://www.vgchartz.com/article/463046/ps5-slim-digital-edition-discounted-to-379-in-the-us-until-december-24/

MSNBC’s Chris Hayes called out Fox News for not showing the full context of Donald Trump’s “enemy within” comments during Vice President Kamala Harris’ interview on the network earlier Wednesday.

The anchor of All In opened his broadcast by calling attention to something that Harris herself did in the sit-down with Fox’s Bret Baier. The clip that the right-wing network showed to Harris as part of Baier’s question was of Trump during his all-female town hall event in Georgia—the one where Trump bizarrely argued he was the “father of IVF.”

In the clip that Fox aired directly to Harris during her interview, Trump wasn’t heard talking about how former House Speaker Nancy Pelosi or Rep. Adam Schiff are the “enemy within.” Instead, Fox made it so Harris had to react to him talking more mildly about “phony investigations.” The network omitted Trump’s line about “the enemy within.”

Read more at The Daily Beast.

I never completed the original Red Dead Redemption, but not for the usual reasons of being terrible at the game, or thinking that open worlds are too big and boring these days and I just want to lie down forever and watch anime. I never finished it because my Xbox 360 version was not, in practice, an open world game, but a lonely farm at the bottom of a vortex of butchered spacetime. In the prologue, reformed outlaw John Marston confronts an old bandit acquaintance and gets himself roundly shot to bits. He’s rescued by local rancher Bonnie MacFarlane, who nurses him back to health and gives him a few odd jobs to warm him up for the next plot point.

Read more

Sunday is cancelled. Book for now!

Read more

My brain is still thawing for the comment freeze, and thus there is sadly no cool industry person to talk to us about books this week. I'm currently reading Tony Tulathimutte’s Rejection. Jia Tolentino wrote about it for the New Yorker. Jia Tolentino also writes very good books. But enough about books, tell me about books! One's you've read, preferably, but I will also accept books you've formed opinions on based on their covers, as is good and proper. Book for now!

Read more

Update:

The full list is now live as promised.

The RPS 100 is our list of the best games to play on PC. It encompasses the full breadth and width of PC gaming stretching back to 1873, but focuses solely on those games that remain great to play today. It's updated yearly by our crack team of writers, and the first half of the 2024 edition is live now.

Read more

The Steam Deck OLED – which is like a Steam Deck but better in almost every way – is getting a new, if potentially more smudge-susceptible Limited Edition. A successor to the translucent version that only went on sale in the US and Canada last year, the Steam Deck OLED: Limited Edition White offers both a snowy look and, for those of us outside North America, the chance to actually buy one. It’ll go on sale November 18th, in all the countries that the Steam Deck currently ships in.

Read more

My strongest and most enduring memory of Grand Theft Auto will always be creasing into complete hysterics watching my mate pile into a crumpled police officer with a wooden baseball bat in GTA 3 after school one time. Young’uns these days just don’t appreciate how revolutionary it was to be able to hit a cop with a thing after he’d already fallen over. Suffice it to say I’ve got good memories of the open world series’ nascent forays into 3D, though never enough to tempt me into revisiting them, especially given the poor reception to Grand Theft Auto: The Trilogy - The Definitive Edition. I can sympathise. I’m annoyed just having to type a semicolon and a dash in the same game name.

If you’re in a similarly non-fussed position (I will never not be annoyed that ‘nonplussed’ doesn’t mean what it sounds like it should mean) I can’t imagine a lighting update that’s been available on the mobile versions for a while is enough to tempt you back. But what is a reporter's job if not pathetically treading water between chunklets of Grand Theft Auto news, upon the publishing of which Graham presses the button to release the nutritious pellets on which we all wholly subsist? I hope he doesn’t read that last sentence. I don’t get my pellet if the syntax becomes too convoluted. Moving swiftly on.

Read more

Will Apple keep one of the few single-fee alternatives to Photoshop available?

The huge four-storey walls of the Lightroom in London are showing ‘Vogue: Inventing the Runway'.

New NatGeo documentary was directed by the same duo who brought us the Oscar-winning Free Solo.

The inaugural Red Lorry Film Festival in 2024 saw over 100 international films across various categories and languages

Let’s dive in earlier this month to make up for last month’s slightly late edition. A new month and season …

Continue reading "The Best ‘Marvel Snap’ Meta Decks – September 2024 Edition"

Apple just announced October 2024’s new Apple Arcade games with NBA 2K25 Arcade Edition as the headliner. Following yesterday’s news …

Continue reading "‘NBA 2K25 Arcade Edition’ Headlines October 2024’s New Apple Arcade Releases With Three App Store Greats"

For our last full controller review on TouchArcade, I’ve been using the Victrix Pro BFG Tekken 8 Rage Art Edition …

Continue reading "Victrix Pro BFG Tekken 8 Rage Art Edition Controller Review – Customizable, Comfortable, but Lacking in Ways"

The office of the Additional Director General of Foreign Trade (CLA DGFT) has announced an Export Obligation Discharge Certificate (EODC) Camp scheduled from November 11 to 22, 2024. The camp is

Two exclusive conferences focusing on "Reference Material (RM) Producers" organized by National Accreditation Board for Testing and Calibration Laboratories (NABL) are scheduled to be held on January 10,

Olivia Friett, editor of Medical Plastics News takes a look at the current regulatory landscape.

Even by the already-painfully-embarrassingly-low standards of clinical trial enrollment in general, patient enrollment in cancer clinical trials is slow. Horribly slow. In many cancer trials, randomizing one patient every three or four months isn't bad at all – in fact, it's par for the course. The most
commonly-cited number is that only 3% of cancer patients participate in a trial – and although exact details of how that number is measured are remarkably difficult to pin down, it certainly can't be too far from reality.

Ultimately, the cost of slow enrollment is borne almost entirely by patients; their payment takes the form of fewer new therapies and less evidence to support their treatment decisions.

So when a couple dozen thousand of the world's top oncologists fly into Chicago to meet, you'd figure that improving accrual would be high on everyone’s agenda. You can't run your trial without patients, after all.

But every year, the annual ASCO meeting underdelivers in new ideas for getting more patients into trials. I suppose this a consequence of ASCO's members-only focus: getting the oncologists themselves to address patient accrual is a bit like asking NASCAR drivers to tackle the problems of aerodynamics, engine design, and fuel chemistry.

Nonetheless, every year, a few brave souls do try. Here is a quick rundown of accrual-related abstracts at this year’s meeting, conveniently sorted into 3 logical categories:

1. As Lord Kelvin may or may not have said, “If you cannot measure it, you cannot improve it.”

• Abstract e15572: Inadequate data availability on clinical trial accrual and its effect on progress in cancer research

Probably the most sensible of this year's crop, because rather than trying to make something out of nothing, the authors measure exactly how pervasive the nothing is. Specifically, they attempt to obtain fairly basic patient accrual data for the last three years' worth of clinical trials in kidney cancer. Out of 108 trials identified, they managed to get – via search and direct inquiries with the trial sponsors – basic accrual data for only 43 (40%).

That certainly qualifies as “terrible”, though the authors content themselves with “poor”.

Interestingly, exactly zero of the 32 industry-sponsored trials responded to the authors' initial survey. This fits with my impression that pharma companies continue to think of accrual data as proprietary, though what sort of business advantage it gives them is unclear. Any one company will have only run a small fraction of these studies, greatly limiting their ability to draw anything resembling a valid conclusion.

• Abstract TPS6645: Predictors of accrual success for cooperative group trials: The Cancer and Leukemia Group B (Alliance) experience

CALGB investigators look at 110 trials over the past 10 years to see if they can identify any predictive markers of successful enrollment. Unfortunately, the trials themselves are pretty heterogeneous (accrual periods ranged from 6 months to 8.8 years), so finding a consistent marker for successful trials would seem unlikely.

And, in fact, none of the usual suspects (e.g., startup time, disease prevalence) appears to have been significant. The exception was provision of medication by the study, which was positively associated with successful enrollment.

The major limitation with this study, apart from the variability of trials measured, is in its definition of “successful”, which is simply the total number of planned enrolled patients. Under both of their definitions, a slow-enrolling trial that drags on for years before finally reaching its goal is successful, whereas if that same trial had been stopped early it is counted as unsuccessful. While that sometimes may be the case, it's easy to imagine situations where allowing a slow trial to drag on is a painful waste of resources – especially if results are delayed enough to bring their relevance into question.

Even worse, though, is that a trial’s enrollment goal is itself a prediction. The trial steering committee determines how many sites, and what resources, will be needed to hit the number needed for analysis. So in the end, this study is attempting to identify predictors of successful predictions, and there is no reason to believe that the initial enrollment predictions were made with any consistent methodology.

2. If you don't know, maybe ask somebody?

• Abstract 8592: Strategies to overcome barriers to accrual (BtA) to NCI-sponsored clinical trials: A project of the NCI-Myeloma Steering Committee Accrual Working Group (NCI-MYSC AWG)
  
• Abstract 1596: Rapid online feedback to improve clinical trial accrual: CODEL anaplastic glioma (AG) (NCCTG/Alliance N0577) as a model

With these two abstracts we celebrate and continue the time-honored tradition of alchemy, whereby we transmute base opinion into golden data. The magic number appears to be 100: if you've got 3 digits' worth of doctors telling you how they feel, that must be worth something.

In the first abstract, a working group is formed to identify and vote on the major barriers to accrual in oncology trials. Then – and this is where the magic happens – that same group is asked to identify and vote on possible ways to overcome those barriers.

In the second, a diverse assortment of community oncologists were given an online survey to provide feedback on the design of a phase 3 trial in light of recent new data. The abstract doesn't specify who was initially sent the survey, so we cannot tell response rate, or compare survey responders to the general population (I'll take a wild guess and go with “massive response bias”).

Market research is sometimes useful. But what cancer clinical trial do not need right now are more surveys are working groups. The “strategies” listed in the first abstract are part of the same cluster of ideas that have been on the table for years now, with no appreciable increase in trial accrual.

3. The obligatory “What the What?” abstract

• Abstract 6564: Minority accrual on a prospective study targeting a diverse U.S. breast cancer population: An analysis of Wake Forest CCOP research base protocol 97609

The force with which my head hit my desk after reading this abstract made me concerned that it had left permanent scarring.

If this had been re-titled “Poor Measurement of Accrual Factors Leads to Inaccurate Accrual Reporting”, would it still have been accepted for this year’s meeting? That's certainly a more accurate title.

Let’s review: a trial intends to enroll both white and minority patients. Whites enroll much faster, leading to a period where only minority patients are recruited. Then, according to the authors, “an almost 4-fold increase in minority accrual raises question of accrual disparity.” So, sites will only recruit minority patients when they have no choice?

But wait: the number of sites wasn't the same during the two periods, and start-up times were staggered. Adjusting for actual site time, the average minority accrual rate was 0.60 patients/site/month in the first part and 0.56 in the second. So the apparent 4-fold increase was entirely an artifact of bad math.

This would be horribly embarrassing were it not for the fact that bad math seems to be endemic in clinical trial enrollment. Failing to adjust for start-up time and number of sites is so routine that not doing it is grounds for a presentation.

The bottom line

What we need now is to rigorously (and prospectively) compare and measure accrual interventions. We have lots of candidate ideas, and there is no need for more retrospective studies, working groups, or opinion polls to speculate on which ones will work best.  Where possible, accrual interventions should themselves be randomized to minimize confounding variables which prevent accurate assessment. Data needs to be uniformly and completely collected. In other words, the standards that we already use for clinical trials need to be applied to the enrollment measures we use to engage patients to participate in those trials.

This is not an optional consideration. It is an ethical obligation we have to cancer patients: we need to assure that we are doing all we can to maximize the rate at which we generate new evidence and test new therapies.

[Image credit: Logarithmic turtle accrual rates courtesy of Flikr user joleson.]

Bill White, VP of Real Estate Lending for NASA FCU, speaks to current housing market conditions, as well as the new Family Mortgage and other options from NASA FCU.

Video impression Ross Sea Cruise

La French Touch by Martell

Chef Antonio Iocchi from Zo�s Kitchen introduces new ways to taste the Mediterranean

The Est�e Edit by Estee Lauder brand video with Guest Editors Kendall Jenner and Irene Kim

puritanical goons do their best to cover up the Not in NSFW images.

Imagine, if you will: an entire wargame, with strategic depth and intriguing possibilities . . . and the rules fit on one page.

If you're a long-time fan of Steve Jackson Games (or you saw the Daily Illuminator post from a couple of weeks ago), you know where we're going with this. One-Page Bulge – originally released in 1980 – did exactly what its title suggests, with Steve Jackson flexing his inimitable game-design skills to deliver a Battle of the Bulge wargame where the rules fit on one sheet of 8.5" × 11" double-sided paper.

This classic game is back with a new edition: One-Page Bulge Second Edition – in time for the 80th anniversary of the pivotal battle itself!

Thanks to Kickstarter (and fans like you), this updated version funded in 40 minutes! In honor of that success, we're providing a few more details about what makes it worth checking out.

One-Page Bulge Second Edition is being updated by Steve Jackson and wargame designer Dana Lombardy – two Hall of Fame designers working together to bring this classic game to a modern era. Find their behind-the-scenes insight about the new version on YouTube!

Some highlights of this edition include:

• New Random Event cards, with exciting events to represent unexpected battlefield surprises.
• A full-color mounted map.
• High-quality components, with two styles of counter sets to choose from (or get them both!).

An illustrated historical guide is also part of this project, bringing this landmark moment to life.

Suitable for solo gaming or two players, One-Page Bulge Second Edition is history in the making. But hurry! The Kickstarter ends in 10 days, on November 14!

– Steven Marsh

Warehouse 23 News: So Real, And Yet So Not

Not everything that's impossible is magical; sometimes it's just really impractical. GURPS Fantasy-Tech 1: The Edge of Reality is an assortment of pre-modern tech that never existed (probably), but might have, or was believed to exist, or was close to working but didn't. Grab a gun-sword, peruse Leonardo da Vinci's sketches, and download the impossible today from Warehouse 23!